Schizophrenia News and Research

Latest Schizophrenia News and Research

Eli Lilly to pay $1.415 billion for off-label promotion of Zyprexa

American pharmaceutical giant Eli Lilly and Company today agreed to plead guilty and pay $1.415 billion for promoting its drug Zyprexa for uses not approved by the Food and Drug Administration (FDA), the Department of Justice announced today.

19 Jan 2009

FDA issues complete response letter for SAPHRIS (asenapine) sublingual tablets in acute treatment of schizophrenia and bipolar disorder

Schering-Plough Corporation has announced that the U.S. Food and Drug Administration (FDA) has issued a complete response letter for SAPHRIS (asenapine) sublingual tablets in the acute treatment of schizophrenia in adults and in the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy.

15 Jan 2009

Even small amounts of exercise good for people with serious mental illnesses

A new study from Indiana University suggests that even meager levels of physical activity can improve the mood of people with serious mental illnesses (SMI) such as bipolar disorder, major depression and schizophrenia.

15 Jan 2009

Genetic variation cues social anxiety in monkeys and humans

A genetic variation involving the brain chemical serotonin has been found to shape the social behavior of rhesus macaque monkeys, which could provide researchers with a new model for studying autism, social anxiety and schizophrenia.

15 Jan 2009

Researchers study asymmetry in the brain

A tug-of-war between the two sides of the brain causes it to become asymmetrical, according to research published today in the journal Neuron.

15 Jan 2009

Delusions associated with consistent pattern of brain injury

A new study provides a novel theory for how delusions arise and why they persist.

13 Jan 2009

Missing DNA the culprit in epilepsy?

An international team of scientists have identified a genetic risk factor for epilepsy which may lead to a better understanding of what causes the seizures and the development of new treatments for the condition.

12 Jan 2009

Lilly receives complete response letter for Olanzapine LAI for treatment of schizophrenia

Eli Lilly and Company has announced that it received a complete response letter from the U.S. Food and Drug Administration (FDA) for olanzapine long-acting injection (LAI) for acute and maintenance treatment of schizophrenia in adults.

7 Jan 2009

Study looks at brain and movement planning

When you first notice a door handle, your brain has already been hard at work. Your visual system first sees the handle, then it sends information to various parts of the brain, which go on to decipher out the details, such as color and the direction the handle is pointing. As the information about an object is sent further along the various brain pathways, more and more details are noticed-in that way, a simple door handle turns into a silver-plated-antique-style-door-handle-facing-right.

18 Dec 2008

Schizophrenia and autism may share common origin

Schizophrenia and autism probably share a common origin, hypothesises Dutch researcher Annemie Ploeger following an extensive literature study.

17 Dec 2008

Borderline personality disorder more common than schizophrenia

According to the National Institute of Mental Health, borderline personality disorder (BPD) is more common than schizophrenia or bipolar disorder and is estimated to affect 2 percent of the population.

16 Dec 2008

Study looks at how parental age affects the mental functioning of offspring

Tel Aviv University researchers found in several consecutive studies that older dads are more likely to have boys with autism and lower IQs. Most recently, they found that the older a father's age, the greater the chance that his son will display poor social abilities as a teen.

15 Dec 2008

Paliperidone palmitate shows positive results for treatment of schizophrenia

Paliperidone palmitate, an investigational long-acting therapy (LAT) demonstrated statistically significant symptom control compared with placebo according to the results of a 13-week study.

14 Dec 2008

Stressed-out mice reveal role of epigenetics in behavior

Research conducted by a team in Switzerland suggests that a family of genes involved in regulating the expression of other genes in the brain is responsible for helping us deal with external inputs such as stress.

12 Dec 2008

Protein FKBP12 provides new insights into understanding autism

Researchers at New York University's Center for Neural Science and the Baylor College of Medicine have identified a protein that when removed from mice results in behaviors that are akin to those with autism and obsessive-compulsive disorders.

10 Dec 2008

Decreased levels of binding gene affect memory and behavior

Reducing the activity of a gene called FKBP12 in the brains of mice affected neuron-to-neuron communication (synapse) and increased both fearful memory and obsessive behavior, indicating the gene could provide a target for drugs to treat diseases such as autism spectrum disorder, obsessive-compulsive disease and others, said researchers from Baylor College of Medicine in Houston in a report in the current issue of the journal Neuron.

10 Dec 2008

Brain deletion of FK506-binding protein enhances repetitive behaviors in mice

A new study reveals a link between dysregulation of a common signaling pathway and repetitive behaviors similar to those associated with multiple neurological and neurodegenerative disorders including, autism spectrum disorders, obsessive compulsive disorder, schizophrenia, and Huntington's disease.

10 Dec 2008

New clues to the roots of epilepsy, autism, schizophrenia

Rice University researchers have found a potential clue to the roots of epilepsy, autism, schizophrenia and other neurological disorders.

10 Dec 2008

AstraZeneca and Targacept announce results from trial of AZD3480 for cognitive dysfunction in schizophrenia

AstraZeneca and Targacept, Inc. havey announced top-line results from a Phase IIb clinical trial of AZD3480 (TC-1734) conducted by AstraZeneca in cognitive dysfunction in schizophrenia (CDS), known as the HALO trial.

10 Dec 2008

Large study looks at genetic risks for schizophrenia and bipolar disorder

A multi-institution team of investigators led by researchers at the Keck School of Medicine of the University of Southern California (USC) has received $19 million in funding from the National Institutes of Mental Health (NIMH) for a groundbreaking effort to collect genetic information on tens of thousands of patients in order to study the genetic risks for schizophrenia and bipolar disorder.

3 Dec 2008